Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...